Due to the lack of effective strategies on the treatment of castration resistant prostate cancer (CRPC), we established a multifunctional nanoplatform (GNS@IR820/DTX-CD133) for the synergistic photothermal therapy (PTT)/photodynamic therapy (PDT)/chemotherapy (CT) under the monitoring of multimodal near-infrared (NIR) fluorescence/photoacoustic (PA) imaging. Benefiting from the guided effect of CD133 antibody, GNS@IR820/DTX-CD133 can targetedly deliver the loaded drug to the tumor tissues, which can further contribute to the combined therapeutic effect. Our experimental results prove that the bio-distribution of GNS@IR820/DTX-CD133 can be monitored with NIR fluorescence and PA imaging. In addition, the application of GNS@IR820/DTX-CD133 for in vitro and in vivo therapy achieves the excellent antitumor effects of the synergistic PTT/PDT/CT strategies under the NIR-light irradiation. Therefore, as a multifunctional nanoplatform integrating the PTT/PDT/CT strategies with tumor multimodal imaging or drug tracing, GNS@IR820/DTX-CD133 has the great potential for clinical applications in the antitumor therapy of CRPC.

由于缺乏有效的治疗去势抵抗性前列腺癌（CRPC）的策略，我们建立了多功能纳米平台（GNS @ IR820 / DTX-CD133）用于协同光热疗法（PTT）/光动力疗法（PDT）/化学疗法（ CT）在多模式近红外（NIR）荧光/光声（PA）成像的监视下。得益于CD133抗体的指导作用，GNS @ IR820 / DTX-CD133可以将负载的药物靶向递送至肿瘤组织，从而进一步有助于联合治疗作用。我们的实验结果证明，可以使用NIR荧光和PA成像监测GNS @ IR820 / DTX-CD133的生物分布。此外，GNS @ IR820 / DTX-CD133的用于应用程序在体外和体内该疗法在近红外光照射下获得了协同PTT / PDT / CT策略的出色抗肿瘤作用。因此，作为将PTT / PDT / CT策略与肿瘤多模态成像或药物追踪相结合的多功能纳米平台，GNS @ IR820 / DTX-CD133在CRPC的抗肿瘤治疗中具有巨大的临床应用潜力。